EMERYVILLE, Calif., Aug. 3 /PRNewswire/ -- KineMed, Inc., a pathway-based drug discovery and development company, announced today the completion of a $15 million convertible notes offering. The offering was led by a direct investment from Stanford Financial Group, joined by existing investors from previous financing rounds. Ledgemont Capital served as placement agent.
